Manager, Corporate Accounting & Consolidations

Responsibilities Lead and manage monthly/quarterly/annual close and consolidation activities to ensure accurate, complete, and timely consolidated results. Oversee consolidation processes, including intercompany eliminations, currency translation, equity accounting, and system consolidations. Ensure compliance with U.S. GAAP, internal accounting policies, and external reporting requirements. Partner with regional finance, FP&A, tax, and controllership to resolve complex accounting and consolidation issues. Review and analyze consolidated financial statements and variance drivers; provide clear explanations to senior leadership. Support internal and external audits by coordinating documentation, responding to inquiries, and resolving issues. Drive process standardization, automation, and continuous improvement across close and consolidation. Lead, coach, and develop team members; foster accountability, collaboration, and continuous learning. Qualifications Bachelor’s degree in Accounting, Finance, or related field (required). Master’s degree in Accounting, Finance, or MBA (preferred). Typically 6-8 years of progressive accounting/financial close/consolidation experience, including people leadership (required). Strong knowledge of U.S. GAAP and financial reporting requirements (required). Hands-on experience with consolidation systems/enterprise platforms (e.g., Hyperion, OneStream, SAP, or similar) (required). Strong analytical, problem-solving, and communication skills; ability to explain complex accounting matters (required). Experience partnering with auditors and cross-functional stakeholders (required). Preferred Global matrixed experience in a regulated industry. Carve-outs/separations/transformations experience. Process improvement and system enhancement success. CPA or equivalent certification. Advanced Excel and financial reporting tool proficiency. Ability to manage complex close timelines across multiple entities/geographies. Other English required. Travel up to 10% (primarily domestic). #J-18808-Ljbffr Scorpion Therapeutics